Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirum Pharmaceuticals Inc (NQ: MIRM ) 39.61 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mirum Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference November 20, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire 11 Analysts Have This to Say About Mirum Pharmaceuticals November 20, 2023 Via Benzinga Mirum Pharmaceuticals Presents New Data at The Liver Meeting® November 13, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Analyst Ratings for Mirum Pharmaceuticals November 03, 2023 Via Benzinga Earnings Outlook For Mirum Pharmaceuticals November 01, 2023 Via Benzinga Analyst Ratings for Mirum Pharmaceuticals October 09, 2023 Via Benzinga Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference November 03, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Present New Data at The Liver Meeting® October 30, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 October 27, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Analyst Ratings for Mirum Pharmaceuticals September 13, 2023 Via Benzinga Where Mirum Pharmaceuticals Stands With Analysts August 21, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 October 24, 2023 Via Benzinga Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis October 17, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire 7 Small-Cap Stocks That Get the Nod from Wall Street October 11, 2023 Although small-cap stocks tend to be extremely risky, these compelling ideas just happen to get the nod from Wall Street analysts. Via InvestorPlace Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN October 07, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis October 02, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting September 26, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Why Shares of Travere Therapeutics Are Slumping Thursday September 21, 2023 A mixed trial could hurt a kidney drug's chances of full approval. Via The Motley Fool Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference September 21, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023 September 20, 2023 Via Benzinga Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer September 11, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 08, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences September 06, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Around $4M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying September 06, 2023 Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades. Via Benzinga Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics September 05, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals September 05, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.